Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04589611 · ClinicalTrials.gov registry record · Phase 1
Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA
A Phase 1 study of Osteoarthritis and Post-traumatic Osteoarthritis, sponsored by J L Marsh.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04589611 is a Phase 1 study of Osteoarthritis and Post-traumatic Osteoarthritis that has completed, run by J L Marsh. The registered enrollment target is 5 participants, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04589611, a Phase 1 study of Osteoarthritis and Post-traumatic Osteoarthritis, has completed, sponsored by J L Marsh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a small-scale proof-of concept clinical trial of amobarbital as a treatment to prevent post-traumatic osteoarthritis in fractured ankle joints. The study is a double blind, prospective, randomized, placebo-controlled, stepwise trial. Amobarbital will be delivered to ankle joints in solution with hyaluronic acid (HA) as a vehicle. Amobarbital/HA injections (active dose) will be compared to HA alone (placebo dose). Our primary goal is to confirm safety, but we will also assess whether treatment improves chondrocyte viability and decreases synovial inflammation. The intervention that will be utilized has proven to be effective using vitro and in vivo models. The study team will assess safety and begin to evaluate efficacy of amobarbital/Gel-One in patients having sustained tibial pilon fractures. The study team will use advanced imaging-based methods we have developed to characterize how joints subjected to varying levels of fracture severity and residual elevated contact stress respond in treated and control groups.
Conditions Studied
Interventions
- DRUG amobarbital/Gel-One (one dose)
- DRUG Placebo (single dose)
- DRUG amobarbital/Gel-One (two doses)
- DRUG Placebo (two doses)
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04589611
The ClinicalTrials.gov registry entry for NCT04589611 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (99% lower). The listed sponsor is J L Marsh, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 4 interventions - of which amobarbital/Gel-One (one dose) is the first listed.
NCT04589611 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT04589611 about?
NCT04589611 is a clinical study titled "Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA". This is a small-scale proof-of concept clinical trial of amobarbital as a treatment to prevent post-traumatic osteoarthritis in fractured ankle joints. The study is a double blind, prospective, randomized, placebo-controlled, stepwise trial. Amobarbital will be delivered to ankle joints in solution ...
What is the current status of trial NCT04589611?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-07-20. Estimated completion is 2023-12-01.
What conditions does trial NCT04589611 study?
This clinical trial studies the following conditions: Osteoarthritis, Post-traumatic Osteoarthritis.
What interventions are being tested in trial NCT04589611?
The interventions under investigation include: amobarbital/Gel-One (one dose) (DRUG), Placebo (single dose) (DRUG), amobarbital/Gel-One (two doses) (DRUG), Placebo (two doses) (DRUG).
Who is sponsoring clinical trial NCT04589611?
This trial is sponsored by J L Marsh, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04589611 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sustained Acoustic Medicine for Osteoarthritis Pain
RECRUITING · Phase 1
-
A Study With GLPG1972 in Osteoarthritis Subjects
COMPLETED · Phase 1
-
Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis
COMPLETED · Phase 1
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System
RECRUITING
-
Reliability of Pupil Response to Acute Pain
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.